A standardised frankincense extract reduces disease activity in relapsing-remitting multiple sclerosis (the SABA phase IIa trial).
Stürner KH, Stellmann JP, Dörr J, Paul F, Friede T, Schammler S, Reinhardt S, Gellissen S, Weissflog G, Faizy TD, Werz O, Fleischer S, Vaas LAI, Herrmann F, Pless O, Martin R, Heesen C.
Stürner KH, et al. Among authors: heesen c.
J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):330-338. doi: 10.1136/jnnp-2017-317101. Epub 2017 Dec 16.
J Neurol Neurosurg Psychiatry. 2018.
PMID: 29248894
Clinical Trial.